Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12702799 | 0.99 | TRPV1 (0.46) | ICMTTRPV1PPARGPPARDPPARA | |
| SCHEMBL8026218 | 0.92 | ALDH1A1 (0.43) | TRPV1PPARGPPARDPPARADNMT1 | |
| SCHEMBL8010389 | 0.91 | BACE1 (0.53) | ICMTTRPV1PPARGPPARDPPARA | |
| SCHEMBL8020241 | 0.90 | BACE1 (0.51) | ICMTTRPV1PPARGPPARDPPARA | |
| SCHEMBL8019433 | 0.88 | BACE1 (0.57) | TRPV1PPARGPPARDPPARADNMT1 | |
| SCHEMBL27639554 | 0.87 | PPARG (0.45) | ICMTTRPV1PPARGPPARDPPARA | |
| SCHEMBL8011289 | 0.82 | PPARG (0.46) | ICMTTRPV1PPARGPPARDPPARA | |
| SCHEMBL12702765 | 0.81 | PPARG (0.47) | ICMTTRPV1PPARGPPARDPPARA | |
| SCHEMBL8011278 | 0.76 | BACE1 (0.55) | PPARGPPARDPPARADNMT1SIRT5 | |
| SCHEMBL1587489 | 0.76 | ACHE (0.48) | TRPV1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| WO-2009098287-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PSEN1, PARK7, APP | ICMT 433/4885TRPV1 712/4885PPARG 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.